Genetic Engineering & Biotechnology News, March 19, 2007 THE WOODLANDS - Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company involved in the development and commercialization of cell therapies, today reported financial results for the year ended December 31, 2006 and provided an update on its progress. David McWilliams, chief executive officer of Opexa, commented, "This has been an extraordinary year for Opexa, which culminated with the commencement at the end of November of our Phase IIb trial in multiple sclerosis with our lead drug candidate Tovaxin. We have 35 U.S. clinical sites actively recruiting patients and now have more than 110 patients admitted to the trial, which, I believe, speaks to the need for effective, patient-friendly therapies for this debilitating disease." McWilliams continued, "We are also pleased with the progress of our other preclinical programs: The initiation of preclinical animal studies of Opexa's monocyte-derived pancreatic islet cells being conducted at the University of Texas Medical Branch - Galveston. These studies, if successful, will form the foundation for the Company's preclinical diabetes program.